PDS Biotechnology (NASDAQ:PDSB - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect PDS Biotechnology to post earnings of ($0.31) per share for the quarter.
PDS Biotechnology Stock Up 0.7 %
Shares of NASDAQ:PDSB traded up $0.01 during trading on Friday, reaching $1.37. 172,720 shares of the stock were exchanged, compared to its average volume of 565,103. The stock has a fifty day moving average of $1.42 and a two-hundred day moving average of $2.22. PDS Biotechnology has a 1-year low of $1.13 and a 1-year high of $4.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The firm has a market cap of $52.32 million, a price-to-earnings ratio of -1.18 and a beta of 1.68.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on PDSB. B. Riley decreased their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Monday, November 25th. HC Wainwright reissued a "buy" rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Thursday, March 13th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.
Read Our Latest Research Report on PDS Biotechnology
About PDS Biotechnology
(
Get Free Report)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Featured Articles
Before you consider PDS Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.
While PDS Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
